Ready for the Talk
"Diet, exercise, oral medications, and I’m still not controlled."
- Ready for the Talk

The average patient may have spent about 5 years with an A1C >8% and nearly 10 years with an A1C >7% prior to insulin initiation.3

You may want to have the insulin talk sooner

Value of Timely Insulin Therapy for Patients with T2DM

Rethinkinsulin.com Typical course of type 2 diabetes

As T2DM progresses, many patients may eventually require insulin therapy to achieve or maintain glycemic control.1 According to retrospective data from 1994 to 2002, the average patient had suboptimal blood glucose controla for about 10 years prior to being started on insulin. From time of diagnosis to insulin initiation, the average patient may have spent about 5 years with an A1C > 8% and nearly 10 years with an A1C >7%.3

  • Insulin is an effective medication to lower blood glucose levels.1
  • Getting blood glucose under control is important.2
Next >

Important Safety Information for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Please click here for full prescribing information

a.Glucose control was defined as A1C >7%

References: 1. Nathan DM et al. Diabetes Care. 2009;32(1):193-203.
2. Nathan DM. N Engl J Med. 2002;347(17):1342-1349.
3. Brown JB, Nichols GA, Perry A. Diabetes Care. 2004;27(7):1535-1540.